Tesamorelin and Ipamorelin Together: What Is Known
Tesamorelin and Ipamorelin taken together: what each one is, how each is regulated, and what is known about combining them.
Timing, interactions and safety
Evidence for the combination
No studies tested these together (PubMed search: 6 results, 2 Oct 2026).
Side by side
Showing 8 of 13 fields where the two differ. Category, PCAC vote, Jul 2026, WADA, Evidence strength, Named in FDA warning letters, 2026 are the same or both unknown.
| Field | Tesamorelin | Ipamorelin |
|---|---|---|
| Class | GHRH analog | GHRP (ghrelin receptor agonist) |
| Also called | tesa, Egrifta | ipa, ipam |
| Category | Growth hormone | Growth hormone |
| FDA status | FDA approved (Egrifta) | Not FDA approved · research chemical |
| PCAC vote, Jul 2026 | Not on the Jul 2026 agenda | Not on the Jul 2026 agenda |
| WADA | Prohibited by WADA (S2.2.4)Tesamorelin is named as a GHRH analogue in S2.2.4 (growth hormone releasing factors), prohibited at all times. Tesamorelin is also an FDA-approved medicine; an athlete would need a therapeutic use exemption. | Prohibited by WADA (S2.2.4)Ipamorelin is named as a growth hormone secretagogue in S2.2.4, prohibited at all times. |
| Anti-doping detection |
|
|
| Half-life | 11 minutessubcutaneous (EGRIFTA WR 1.28 mg) · FDA label (Egrifta WR) | 2 hours terminal half-lifeintravenous infusion (15 min) · Pharmaceutical research 1999, PMID 10496658 |
| Evidence strength | Human RCT evidence, 4 of 4Strongest: eNeurologicalSci 2026, PMID 42382101 | Human RCT evidence, 4 of 4Strongest: International journal of colorectal disease 2014, PMID 25331030 |
| Human studies we summarised | 12 human (11 randomized or controlled) of 16 summarised | 2 human (2 randomized or controlled) of 12 summarised |
| Typical study doses |
|
|
| Vial sizes sold | 2 mg, 5 mg, 10 mg, 20 mg | 2 mg, 5 mg, 10 mg |
| Named in FDA warning letters, 2026 | Yes (24 Aug 2026) | Yes (24 Aug 2026) |
Sold pre-mixed too
Some vials combine these peptides. The blend calculator shows the dose of each component per draw.
Two peptides, two different receptors
Tesamorelin's label describes it as acting on the same receptor as the hypothalamic hormone that normally triggers growth hormone release.[5]
Ipamorelin is not a GHRH-type peptide: pharmacology work in rat pituitary cells and animals found it releases growth hormone through a GHRP-like receptor instead.[16]
In conscious swine, ipamorelin released growth hormone without raising ACTH or cortisol beyond what GHRH did, unlike GHRP-6 and GHRP-2, which raised them. This is an animal result.[16]
Has anyone studied the two together?
A PubMed title and abstract search on 2 Oct 2026 for ipamorelin together with tesamorelin matched 6 records. The abstracts cached for all six are review articles, not a trial that gave both peptides.
Calculated from pubmed query (ipamorelin[tiab]) AND (tesamorelin[tiab] OR Egrifta[tiab] OR TH9507[tiab] OR "TH-9507"[tiab]); records matched 6; search date 2026-10-02. Formula: records_matched = PubMed count recorded in combinations.json for the query on search_date
One of those reviews, on performance-enhancing peptides, cites uncertainty about product composition, dose and stacking practices in unregulated supply chains.[17]
What each peptide has on its own
Tesamorelin's first trial assigned 412 patients with HIV and excess abdominal fat to daily tesamorelin or placebo for 26 weeks.[15]
The ipamorelin randomised trial in the cached sources was a phase 2 proof-of-concept study in postoperative ileus after abdominal surgery.[12]
Label cautions and legal status
The Egrifta WR label asks for monitoring when it is used with other drugs metabolised by CYP450 liver enzymes.[5]
The same label contraindicates tesamorelin in pregnancy.[5]
Ipamorelin has no FDA-approved product: a Drugs@FDA search for the ingredient returned nothing.[18]
The current WADA Prohibited List names tesamorelin in its GHRH class and ipamorelin among the growth hormone secretagogues.[2]
Common questions
Is there a tesamorelin ipamorelin blend?
No approved product contains ipamorelin, so no approved tesamorelin-ipamorelin blend exists.[18]
Tesamorelin vs ipamorelin: which has more human evidence?
Tesamorelin has more: its first trial randomised 412 patients. The cached ipamorelin trial found no significant difference in time to first tolerated meal.[15]
Is ipamorelin on the WADA list?
Yes. Ipamorelin is listed among the growth hormone secretagogues on WADA's current list.[2]
Sources
- 1FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
- 2World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 3An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.Journal of pharmaceutical and biomedical analysis · 2022PMID 35298973Accessed 2 Oct 2026
- 4Advances in the detection of growth hormone releasing hormone synthetic analogs.Drug testing and analysis · 2021PMID 34665524Accessed 2 Oct 2026
- 5EGRIFTA WR (TESAMORELIN) KIT [THERATECHNOLOGIES INC.]FDA label (Egrifta WR), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 6The effect of growth hormone-releasing hormone on cognition and brain connectivity in adults with cognition ranging from normal to mild cognitive impairment.eNeurologicalSci · 2026PMID 42382101Accessed 2 Oct 2026
- 7Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.The lancet. HIV · 2019PMID 31611038Accessed 2 Oct 2026
- 8The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV.The Journal of frailty & aging · 2019PMID 31237318Accessed 2 Oct 2026
- 9Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin.Drug testing and analysis · 2015PMID 25869809Accessed 2 Oct 2026
- 10Simplifying and expanding the screening for peptides <2 kDa by direct urine injection, liquid chromatography, and ion mobility mass spectrometry.Journal of separation science · 2016PMID 26578461Accessed 2 Oct 2026
- 11Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.Pharmaceutical research · 1999PMID 10496658Accessed 2 Oct 2026
- 12Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.International journal of colorectal disease · 2014PMID 25331030Accessed 2 Oct 2026
- 13The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism.Physiology & behavior · 2024PMID 39043357Accessed 2 Oct 2026
- 14PubMed search: (ipamorelin[tiab]) AND (tesamorelin[tiab] OR Egrifta[tiab] OR TH9507[tiab] OR "TH-9507"[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 15Metabolic effects of a growth hormone-releasing factor in patients with HIV.The New England journal of medicine · 2007PMID 18057338Accessed 2 Oct 2026
- 16Ipamorelin, the first selective growth hormone secretagogue.European journal of endocrinology · 1998PMID 9849822Accessed 2 Oct 2026
- 17The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.Frontiers in endocrinology · 2026PMID 42395176Accessed 2 Oct 2026
- 18Drugs@FDA (openFDA) search: active ingredient "ipamorelin"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
Found an error? Report a correction.